Transitional Cell Carcinoma of the Urinary Bladder

Transitional cell carcinoma (TCC) of the urinary bladder is the most common malignant neoplasm of the canine urinary tract, accounting for approximately 1-2% of all canine neoplasms and over 90% of primary bladder tumors in dogs. It arises from the transitional epithelium (urothelium) lining the bladder, ureters, and proximal urethra. TCC is characterized by aggressive local invasion into the bladder wall, urethra, prostate, and adjacent pelvic structures, with a high propensity for metastasis to regional lymph nodes (sublumbar, iliac) and distant sites, most commonly the lungs, liver, and bones. In cats, TCC is less common but exhibits similar biological behavior. The disease is typically diagnosed in older animals, with a mean age of 9-11 years in dogs. Clinical presentation often includes hematuria, stranguria, pollakiuria, and dysuria, which can mimic urinary tract infections (UTIs). Due to its aggressive nature and late diagnosis, the prognosis is generally guarded, with median survival times ranging from 6 to 12 months with treatment. Early detection and multimodal therapy are critical for optimizing outcomes.

The exact etiology of transitional cell carcinoma is multifactorial and not fully understood. In dogs, a well-established risk factor is chronic exposure to certain environmental chemicals, particularly those used in the herbicide and insecticide industries. Specifically, exposure to 4-aminobiphenyl, a component of some pesticides, has been linked to TCC development. Additionally, a genetic predisposition has been identified in certain breeds, notably the Scottish Terrier, Shetland Sheepdog, Beagle, and West Highland White Terrier, suggesting a heritable component. In Scottish Terriers, a genome-wide association study identified a risk haplotype on chromosome 5, and a mutation in the BRCA1 gene has been implicated. Chronic inflammation of the bladder, such as recurrent urinary tract infections or urolithiasis, may also contribute to neoplastic transformation, although the direct causal relationship is debated. In cats, the etiology is less clear, but similar environmental and genetic factors may play a role. Viral oncogenesis has not been definitively established in veterinary TCC, unlike some human bladder cancers. Molecular mechanisms involve dysregulation of oncogenes and tumor suppressor genes, including overexpression of epidermal growth factor receptor (EGFR) and mutations in p53 and PTEN, leading to uncontrolled cell proliferation and invasion.

Transitional cell carcinoma primarily affects dogs, with a higher incidence in females (approximately 1.5-2:1 female-to-male ratio). The mean age at diagnosis is 9-11 years, with a range of 5-15 years. Certain breeds are overrepresented, including Scottish Terriers (with a 20-fold increased risk), Shetland Sheepdogs, Beagles, West Highland White Terriers, and Wirehaired Fox Terriers. Mixed-breed dogs are also affected. In cats, TCC is rare, accounting for less than 1% of feline neoplasms, and is typically seen in older cats (mean age 12 years). No strong breed predilection is noted in cats. Geographic variation may exist due to environmental exposures, but comprehensive epidemiological studies are lacking. The incidence of TCC in dogs is estimated at 0.1-0.2% of all dogs, but it is the most common bladder tumor. No significant seasonal variation is reported. The disease is more common in urban or agricultural areas where pesticide exposure is higher.

Transitional cell carcinoma arises from the urothelial cells lining the bladder. The pathogenesis involves a stepwise accumulation of genetic and epigenetic alterations that lead to cellular dysplasia, carcinoma in situ, and eventually invasive carcinoma. Key molecular pathways include activation of the RAS-MAPK and PI3K-AKT signaling cascades, often driven by mutations in EGFR and other receptor tyrosine kinases. Overexpression of EGFR is seen in up to 70% of canine TCCs, promoting cell proliferation, angiogenesis, and invasion. Loss of tumor suppressor genes, such as p53 and PTEN, leads to unchecked cell cycle progression and resistance to apoptosis. The tumor typically arises in the trigone region of the bladder, which is the most common site, and extends into the urethra and prostate in males. Local invasion occurs through the bladder wall into the surrounding pelvic fat, ureters, and lymphatics. Metastasis occurs via lymphatic and hematogenous routes, with the most common sites being the sublumbar and iliac lymph nodes, lungs, liver, and bones. The tumor induces a desmoplastic response, leading to fibrosis and thickening of the bladder wall. Clinical signs result from irritation of the bladder mucosa, obstruction of the urethra or ureters, and invasion into adjacent structures. Hematuria occurs due to tumor ulceration and necrosis. Secondary bacterial cystitis is common due to compromised mucosal integrity and urinary stasis.

Predisposing factors for transitional cell carcinoma include both intrinsic and extrinsic elements. Intrinsic factors include breed and genetic predisposition, as seen in Scottish Terriers, Shetland Sheepdogs, and Beagles. Age is a significant factor, with older animals (over 7 years) at higher risk. Female sex is a predisposing factor, possibly due to longer exposure to urinary carcinogens or hormonal influences. Extrinsic factors include environmental exposure to herbicides, insecticides, and other chemicals, particularly those containing 4-aminobiphenyl. Obesity has been suggested as a risk factor in some studies, possibly due to altered metabolism of carcinogens. Chronic urinary tract inflammation, such as recurrent UTIs or urolithiasis, may increase the risk, although the evidence is not conclusive. Immunosuppression, either from disease or medication, may also predispose to neoplastic transformation. In cats, chronic lower urinary tract disease may be a risk factor, but data are limited.

Clinical signs of transitional cell carcinoma are often insidious and may be mistaken for a urinary tract infection. The most common signs include hematuria (gross or microscopic), stranguria, pollakiuria, and dysuria. These signs are due to tumor irritation, inflammation, and obstruction. As the tumor grows, it may cause partial or complete urethral obstruction, leading to urinary retention, abdominal distension, and post-renal azotemia. In male dogs, prostatic involvement can cause tenesmus and dyschezia. In advanced cases, signs of metastasis may include weight loss, lethargy, anorexia, and respiratory distress if pulmonary metastases are present. Lameness or bone pain may occur with skeletal metastases. On physical examination, a palpable bladder mass may be detected in some cases, especially if the tumor is large. Rectal examination may reveal a thickened urethra or prostatic enlargement in males. In cats, signs are similar but may be less specific, with vomiting and anorexia more common.

Differential diagnoses for transitional cell carcinoma include: 1) Chronic bacterial cystitis: Presents with similar signs (hematuria, stranguria), but urinalysis typically shows significant pyuria and bacteriuria, and culture is positive. Imaging may show bladder wall thickening but not a discrete mass. Response to antibiotics is expected. 2) Benign polyps or inflammatory pseudotumors: These can mimic TCC on imaging and cystoscopy, but histopathology is required for differentiation. 3) Urolithiasis (bladder stones): Causes hematuria and dysuria, but radiography or ultrasound reveals hyperechoic calculi with acoustic shadowing. 4) Other bladder tumors: Such as leiomyoma, rhabdomyosarcoma, or lymphoma, which are less common but can have similar clinical signs. Histopathology is definitive. 5) Prostatic disease in males: Prostatitis, prostatic hyperplasia, or prostatic adenocarcinoma can cause similar lower urinary tract signs and may be associated with TCC. 6) Urethral obstruction from other causes: Such as strictures, calculi, or foreign bodies. 7) Idiopathic cystitis (feline interstitial cystitis): In cats, this is a common cause of lower urinary tract signs, but imaging and biopsy can differentiate. 8) Renal or ureteral tumors: May cause hematuria but are less common and can be differentiated by imaging.

The diagnostic algorithm for suspected transitional cell carcinoma begins with a thorough history and physical examination, including rectal palpation. Initial laboratory tests include a complete blood count (CBC), serum biochemistry profile, and urinalysis with urine culture. Urinalysis often reveals hematuria and sometimes neoplastic cells on cytology, but cytology has low sensitivity (30-50%) and is not definitive. If TCC is suspected, abdominal ultrasound is the next step, as it can identify a bladder mass, assess wall thickness, and evaluate for lymphadenopathy. Ultrasound-guided fine-needle aspiration (FNA) of the mass can be performed for cytology, but histopathology is preferred for definitive diagnosis. Cystoscopy (transurethral or percutaneous) allows direct visualization and biopsy of the mass. Biopsy is the gold standard for diagnosis. Staging for metastasis includes thoracic radiographs (three views) and abdominal ultrasound. Computed tomography (CT) may be used for more accurate staging, especially for lymph node assessment. If metastasis is suspected, additional imaging such as bone scintigraphy or MRI may be indicated. The World Health Organization (WHO) staging system for canine bladder tumors is used: T1 (superficial), T2 (invasion of bladder wall), T3 (invasion of adjacent organs), N0/N1 (lymph node metastasis), M0/M1 (distant metastasis).

Laboratory findings in transitional cell carcinoma are often non-specific. Complete blood count may show mild anemia due to chronic disease or blood loss. Leukocytosis may be present if secondary infection occurs. Serum biochemistry may be normal in early cases, but with urethral obstruction, azotemia (elevated BUN and creatinine) and hyperkalemia may be seen. Hypercalcemia of malignancy is rare but can occur. Urinalysis typically reveals hematuria (gross or microscopic), proteinuria, and sometimes pyuria. Urine sediment may contain atypical transitional cells, but cytology has low sensitivity. Urine culture is important to rule out concurrent bacterial cystitis, which is present in up to 50% of cases. Urinary biomarkers, such as bladder tumor antigen (BTA) test, have been evaluated but are not widely used due to variable sensitivity and specificity. In dogs, a urine-based test for the BRAF mutation (V595E) has shown high sensitivity and specificity for TCC and can be used as a non-invasive diagnostic aid. This test is commercially available and can be performed on urine samples.

Imaging plays a crucial role in the diagnosis and staging of transitional cell carcinoma. Abdominal radiography may show a soft tissue mass in the bladder region, but it is not sensitive. Contrast cystography (double-contrast) can reveal filling defects or irregular mucosal thickening, but it is less commonly used now. Abdominal ultrasonography is the primary imaging modality, as it can detect a bladder mass, typically located in the trigone, with a broad-based, irregular, and heterogeneous appearance. The mass may protrude into the lumen or cause asymmetric thickening of the bladder wall. Ultrasound also allows assessment of regional lymph nodes (sublumbar, iliac) for enlargement, and evaluation of the kidneys and ureters for hydronephrosis due to obstruction. Doppler ultrasound can assess vascularity of the mass. Thoracic radiographs (three views) are essential for staging, as pulmonary metastases are common. Computed tomography (CT) provides superior anatomical detail and is particularly useful for evaluating the extent of local invasion, especially into the urethra and prostate, and for detecting small pulmonary nodules. CT is also used for radiation therapy planning. Magnetic resonance imaging (MRI) may be used for advanced soft tissue characterization but is less commonly employed. Cystoscopy is both a diagnostic and therapeutic tool, allowing direct visualization of the tumor and biopsy acquisition.

Cytology from fine-needle aspiration (FNA) of a bladder mass can be performed under ultrasound guidance. Smears may show clusters of transitional epithelial cells with criteria of malignancy, including anisocytosis, anisokaryosis, high nuclear-to-cytoplasmic ratio, and prominent nucleoli. However, cytology has limited sensitivity (30-50%) and cannot reliably distinguish TCC from other epithelial tumors or severe inflammation. Histopathology from biopsy is the gold standard for diagnosis. Biopsy can be obtained via cystoscopy, surgery (cystotomy), or percutaneously. Histologically, TCC is characterized by invasive cords and nests of transitional epithelial cells that may show papillary or solid growth patterns. The cells exhibit variable pleomorphism, mitotic activity, and invasion into the lamina propria and muscularis. Grading (I-III) and staging (TNM) are important for prognosis. Immunohistochemistry can be used to differentiate TCC from other tumors; TCC is typically positive for cytokeratin (AE1/AE3), uroplakin III, and sometimes COX-2. Negative staining for vimentin and S100 helps rule out sarcomas and melanoma. In some cases, molecular testing for BRAF mutation can be performed on biopsy tissue.

Treatment of transitional cell carcinoma is multimodal and aims to control local disease, prevent metastasis, and maintain quality of life. The standard of care includes surgical debulking (partial cystectomy) when feasible, followed by chemotherapy. However, complete surgical excision is often impossible due to the trigonal location and invasive nature. Nonsteroidal anti-inflammatory drugs (NSAIDs), particularly piroxicam, are a cornerstone of therapy due to their ability to induce apoptosis and inhibit angiogenesis via COX-2 inhibition. Piroxicam is typically administered at a dose of 0.3 mg/kg PO q24h in dogs, with food to reduce gastrointestinal side effects. Chemotherapy options include mitoxantrone (5.5-6 mg/m² IV q21d) or carboplatin (300 mg/m² IV q21d), often used in combination with piroxicam. Vinblastine (2-3 mg/m² IV q7d) has also shown efficacy. In dogs with urethral obstruction, palliative options include urethral stenting, cystostomy tube placement, or laser ablation. Radiation therapy (definitive or palliative) can be used for local control, especially for non-resectable tumors, but may cause significant side effects. In cats, treatment is similar but with adjusted doses; piroxicam is used at 0.3 mg/kg PO q48-72h due to increased sensitivity to NSAIDs. Supportive care includes management of secondary urinary tract infections with appropriate antibiotics, and management of renal insufficiency if ureteral obstruction occurs. Nutritional support and pain management are important. Novel therapies, such as tyrosine kinase inhibitors (e.g., toceranib) and metronomic chemotherapy, are being explored.

The prognosis for transitional cell carcinoma is guarded to poor. Without treatment, median survival time is approximately 1-3 months after diagnosis. With surgical debulking alone, median survival is around 6 months. With combination therapy (surgery, chemotherapy, and NSAIDs), median survival times range from 6 to 12 months, with some dogs living longer. Factors associated with a worse prognosis include advanced tumor stage (T3), presence of metastasis at diagnosis, high histologic grade, and incomplete surgical margins. Dogs that respond to chemotherapy and NSAIDs may have longer survival. The presence of a BRAF mutation does not appear to affect prognosis. In cats, the prognosis is similarly poor, with median survival times of 6-12 months with treatment. Quality of life is a major consideration, and euthanasia is often elected when the tumor causes intractable obstruction or severe pain.

Follow-up for transitional cell carcinoma is intensive and lifelong. After initial diagnosis and treatment, re-evaluation is recommended every 1-3 months. Each visit should include a physical examination, including rectal palpation, and assessment of clinical signs. Urinalysis and urine culture should be performed to monitor for secondary infections. Serum biochemistry and CBC are recommended to monitor for drug toxicities (e.g., renal, hepatic) and systemic effects. Imaging, typically abdominal ultrasound, is recommended every 2-3 months to assess tumor size and detect metastasis. Thoracic radiographs should be repeated every 3-4 months to screen for pulmonary metastases. If the patient is on chemotherapy, complete blood counts should be checked before each dose to monitor for myelosuppression. Dose adjustments are made based on toxicity. If a cystostomy tube is in place, it requires regular care and monitoring. Owners should be educated on signs of urethral obstruction (straining, anuria) and instructed to seek immediate veterinary care if these occur. Long-term management includes continued NSAID therapy, with periodic monitoring of renal and gastrointestinal status. Adjustments to pain management and supportive care are made as needed.

Pearls: 1) Always consider TCC in older dogs with persistent hematuria and stranguria that do not respond to antibiotic therapy. 2) Urine BRAF mutation testing is a valuable, non-invasive diagnostic tool with high sensitivity and specificity for TCC in dogs. 3) Piroxicam is not just a palliative drug; it has antitumor effects and should be included in the treatment plan unless contraindicated. 4) Cystoscopy is essential for obtaining a definitive biopsy and assessing the extent of the tumor. 5) Staging with thoracic radiographs and abdominal ultrasound is crucial before initiating treatment. Pitfalls: 1) Misdiagnosing TCC as a urinary tract infection and treating with antibiotics alone, delaying definitive diagnosis. 2) Performing a fine-needle aspirate of a bladder mass without ultrasound guidance, which can cause tumor seeding or hemorrhage. 3) Using piroxicam in patients with renal insufficiency or gastrointestinal ulcers without appropriate monitoring. 4) Failing to consider urethral obstruction as a complication, which can be life-threatening. 5) Not recommending referral to a veterinary oncologist for optimal management.

Based on Plumb's Veterinary Drug Handbook, the following protocols are commonly used: 1) Piroxicam: Dogs: 0.3 mg/kg PO q24h, given with food. Cats: 0.3 mg/kg PO q48-72h. Contraindicated in patients with gastrointestinal ulcers, renal disease, or bleeding disorders. Monitor renal and hepatic function. 2) Mitoxantrone: Dogs: 5.5-6 mg/m² IV q21d, diluted in 0.9% NaCl and infused over 15-30 minutes. Monitor for myelosuppression and cardiotoxicity. 3) Carboplatin: Dogs: 300 mg/m² IV q21d, infused over 15-30 minutes. Dose adjustment for renal insufficiency. 4) Vinblastine: Dogs: 2-3 mg/m² IV q7d, as a slow bolus. Monitor for neutropenia. 5) Toceranib (Palladia): Dogs: 2.75-3.25 mg/kg PO q48h, with food. Monitor for gastrointestinal and hematologic toxicities. 6) Metronomic chemotherapy: Cyclophosphamide (10-12.5 mg/m² PO q24h) or chlorambucil (4-5 mg/m² PO q24h) in combination with piroxicam, for long-term control. 7) Antibiotics for secondary infections: Based on culture and sensitivity, e.g., amoxicillin-clavulanate (13.75 mg/kg PO q12h) or enrofloxacin (5-10 mg/kg PO q24h). 8) Analgesics: For pain, e.g., tramadol (2-5 mg/kg PO q8-12h) or gabapentin (5-10 mg/kg PO q8-12h). 9) Gastroprotectants: If NSAIDs are used, consider omeprazole (0.5-1 mg/kg PO q24h) or misoprostol (2-5 µg/kg PO q8h).

Key studies and consensus guidelines: 1) A landmark study by Knapp et al. (1994) demonstrated that piroxicam has antitumor activity in canine TCC, with a response rate of 17% and disease stabilization in 50% of dogs. 2) A randomized trial by Henry et al. (2003) compared mitoxantrone plus piroxicam to piroxicam alone, showing a higher response rate (35% vs. 8%) and longer survival (291 vs. 184 days) in the combination group. 3) A study by Rocha et al. (2000) evaluated carboplatin and piroxicam, reporting a response rate of 31% and median survival of 246 days. 4) The use of vinblastine in combination with piroxicam was evaluated by Arnold et al. (2011), showing a response rate of 33% and median survival of 180 days. 5) The BRAF mutation (V595E) was identified by Decker et al. (2015) and validated as a diagnostic biomarker in urine, with a sensitivity of 85% and specificity of 100%. 6) ACVIM consensus guidelines on the diagnosis and treatment of canine urinary bladder tumors were published in 2016, recommending a multimodal approach and emphasizing the importance of staging. 7) A study by Fulkerson et al. (2016) evaluated toceranib in TCC, showing a biological activity with a median progression-free survival of 15 weeks. 8) For cats, a retrospective study by Wilson et al. (2007) reported a median survival of 6 months with various treatments. 9) The use of urethral stenting for obstructive TCC was described by Weisse et al. (2006), showing successful palliation of clinical signs. 10) A meta-analysis by Boria et al. (2005) confirmed the prognostic significance of tumor stage and grade.